开发阿洛格利口服溶解膜,以优化治疗结果
Sagar Pathade1, Varsha Balkrishna Mane2, Nagesh Aloorkar1
1Satara College of Pharmacy, Degaon, Satara, Maharashtra, India, 415004, affiliated to Dr. Babasaheb Ambedkar Technological University, Lonere (DBATU), Maharashtra, India.
Pharmaceutical research
|June 4, 2025
概括
这项研究开发了Alogliptin酸口服溶解膜 (ODF),通过绕过第一通代谢来改善糖尿病治疗. 开口药片显示药物释放速度快,口服吸收增强,有效降低血糖,为糖尿病管理提供了有前途的替代方案.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 药用化学 医学化学
背景情况:
- 口服药物的第一通代谢可以限制治疗疗效.
- 阿洛格利普丁酸是一种抗糖尿病药物,需要优化输送.
- 快速溶解的膜提供了一种改善药物的生物可用性的潜在策略.
研究的目的:
- 为了制定阿洛格利普丁酸作为口服溶解膜 (ODF).
- 评估ODFs的物理化学特性和体外溶解.
- 在体内评估ODF配方的抗糖尿病活性和治疗益处.
主要方法:
- 阿洛格利普丁酸ODF使用溶剂造方法制备.
- 物理化学表征包括药物含量统一性,表面pH值和FTIR分析.
- 在pH 6.8的酸盐缓冲体中进行了体外溶解研究,随后在老鼠中进行了加速稳定性测试和体内抗糖尿病活性评估.
主要成果:
- 优化的ODF表现出均的药物含量 (98.84±2.22%) 和有利的物理特性.
- 经过FTIR和热分析证实了Alogliptin酸在配方中的稳定性.
- 在糖尿病大鼠中,ODFs在第一小时内显示出有效的口腔粘膜透和快速降低血糖,在24小时内持续有效.
结论:
- 基酸 (Alogliptin benzoate) ODFs为糖尿病管理提供了一个可行的替代方案.
- ODF配方通过改善药物输送和患者遵守来增强治疗效益.
- 这种新的剂量形式促进了更容易的管理,并可能减少第一通代谢.
相关概念视频
Factors Influencing Drug Absorption: Pharmaceutical Parameters
198
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
198
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.1K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.1K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
269
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
269
Glucagon-like Receptor Agonists
438
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
438
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
407
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
407


